Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar O Rohondia

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Current Cancer Drug Targets|February 27, 2020
Updated Review and Perspective on 20S Proteasome Inhibitors in the Treatment of Lung CancerSagar O Rohondia, Zainab Sabry Othman Ahmed, Q Ping Dou
Expert Opinion on Therapeutic Patents|July 28, 2020
Small molecules as antagonists of co-inhibitory pathways for cancer immunotherapy: a patent review (2018-2019)Qiaohong Geng, Sagar O Rohondia, Harras J Khan, et al.
Journal of Perinatal Medicine|September 9, 2019
Academic tweeting in #ObGyn. Where do we stand?Ghanshyam S Yadav, Nupur R Nagarkatti, Sagar O Rohondia, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Current Cancer Drug Targets|February 27, 2020
Updated Review and Perspective on 20S Proteasome Inhibitors in the Treatment of Lung CancerSagar O Rohondia, Zainab Sabry Othman Ahmed, Q Ping Dou
Expert Opinion on Therapeutic Patents|July 28, 2020
Small molecules as antagonists of co-inhibitory pathways for cancer immunotherapy: a patent review (2018-2019)Qiaohong Geng, Sagar O Rohondia, Harras J Khan, et al.
Journal of Perinatal Medicine|September 9, 2019
Academic tweeting in #ObGyn. Where do we stand?Ghanshyam S Yadav, Nupur R Nagarkatti, Sagar O Rohondia, et al.
Pageof 1